GILBERT’S SYNDROME: CURRENT INSIGHTS, OUTCOMES AND THERAPIES

Authors

  • Jakhongir Jasurovich Bakhronov Students of the Samarkand State Medical University, Samarkand, Uzbekistan.
  • Dostonbek Abdurashid ugli Otakulov Students of the Samarkand State Medical University, Samarkand, Uzbekistan.
  • Muhammadjon Nuraliyevich Nigmatullaev Students of the Samarkand State Medical University, Samarkand, Uzbekistan.

Keywords:

unconjugated hyperbilirubinemia, icterus, uridine diphosphoglucose, liver cirrhosis, aglucones, somatostatin.

Abstract

Gilbert’s syndrome (GS) has been known to clinicians for a long time: more than a hundred years have passed since it was described by Augustine Gilbert in 1901. But in recent years there has been a resurgence of interest in it. This is due to the opened possibility of objective genetic confirmation of the diagnosis and long-term (for several decades) study of its consequences and impact on the health of the population. Clinically manifested usually at the threshold of adulthood, this syndrome is in the field of view of both pediatricians and gastroenterologists-hepatologists working with adult patients, therefore, modern ideas about GS are of interest to a wide range of doctors.

References

Farago B. Gilbert’s syndrome / B. Farago, B. Melegh // Orv. Hetil. 2008. Vol. 149. № 27. P. 1277–1282.

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab / J. S. Lee [et al.] // Pharmacogenet. Genomics. 2011. Vol. 21. № 7. P. 365–374.

Gilbert A. La cholemie simple familiale / A. Gilbert, P. Lereboullet // Semaine Medicale. 1901. Vol. 21. P. 241–243.

Gilbert’s syndrome and antiviral therapy of hepatitis C / K. Deterding [et al.] //Ann. Hepatol. 2009. Vol. 8. № 3. P. 246–250.

Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population / A. Tsezou [et al.] // Genet. Test. Mol. Biomarkers. 2009. Vol. 13. № 1. P. 143–146.

Loci from a genome-wide analyses of bilirubin levels are associated with gallstone risk and composition / S. Buch [et al.] // Gastroenterology. 2010. Vol. 139. № 6. P. 1942–1951.

Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome / I. Bernabeu [et al.] // J. Clin. Endocrinol. Metab. 2010. Vol. 95. № 5. P. 2147–2154.

Silva R. F. Bilirubin-Induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholie acid but prevented by ursodeoxycholic acid / R. F. Silva, C. M. Rodrigues, D. Brites // J. Hepatol. 2001. Vol. 34. № 3. P. 402–408, 467–470.

Strassburg C. P. Gilbert-Meulengracht’s syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? // Drug. Metabolism. Rev. 2010. Vol. 42. № 1. P. 168–181.

Downloads

Published

2023-06-15

How to Cite

Bakhronov , J. J., Otakulov , D. A. ugli, & Nigmatullaev , M. N. (2023). GILBERT’S SYNDROME: CURRENT INSIGHTS, OUTCOMES AND THERAPIES. GOLDEN BRAIN, 1(16), 131–135. Retrieved from https://researchedu.org/index.php/goldenbrain/article/view/3717

Issue

Vol. 1 No. 16 (2023): GOLDEN BRAIN

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.